Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)

–ARU-1801 reduced vaso-occlusive events and days in the hospital for patients with severe sickle cell disease– MILLBURN, N.J. and BASEL, Switzerland, May 12, 2022 /PRNewswire/ — Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases,…